Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations

References

• Brøsen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology 1989; 36: 537–547
   PubMed Web of Science ®Google Scholar
• Caldwell J. Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. Toxicology Letters 1992; 64/65: 651–659
   Web of Science ®Google Scholar
• Chundela B., Slechtova R. Excretion of methoxyphenamine and its metabolites in urine. Journal of Chromatography 1976; 119: 609–612
   Google Scholar
• Coutts R. T., Bolaji O. O., Su P., Baker G. B. Metabolism of methoxyphenamine in vitro by a CYP2D6 microsomal preparation. Drug Metabolism and Disposition 1994; 22: 756–760
   PubMed Web of Science ®Google Scholar
• Coutts R. T., Foster B. C., Jones G. R., Myers G. E. Metabolism of N-(n-propyl)amphetamine by Cunninghamella echinulata. Applied and Environmental Microbiology 1979; 37: 429–432
   PubMed Web of Science ®Google Scholar
• C.P.S. Nizoral. Compendium of Pharmaceutical Specialties, 27th edn, C. M. E. Krogh. Canadian Pharmaceutical Association, Ottawa 1992; 761–762
   Google Scholar
• Davis P. J. Microbial models of mammalian drug metabolism. Developments in Industrial Microbiology 1988; 29: 197–229
   Google Scholar
• Eichlebaum M., Gross A. S. The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects. Pharmacology and Therapeutics 1990; 46: 377–394
   Google Scholar
• Foster B. C., Coutts R. T., Pasutto F. M., Mozayai A. Microbial metabolism of phenelzine and pheniprazine. Life Sciences 1988; 42: 285–292
   PubMed Web of Science ®Google Scholar
• Foster B. C., Litster D. L., Wilson D. L., Ormsby E., Dawson B. A. In vitro assessment of cytotoxicity and biotransformation of propranolol in Cunninghamella echinulata. Xenobiotica 1992; 22: 1221–1228
   PubMed Web of Science ®Google Scholar
• Foster B. C., Wilson D. L., Cyr T. D., Moffatt J., Buttar H. S. Influence of pregnancy on the biotransformation and urinary excretion of methoxyphenamine in mice. Biopharmaceutics and Drug Disposition 1994; 15: 860–871
   Google Scholar
• Foster B. C., Wilson D. L., McGilveray I. J. Effect of sparteine and quinidine on the metabolism of methoxyphenamine by Cunninghamella bainieri. Xenobiotica 1989; 19: 445–452
   PubMed Web of Science ®Google Scholar
• Kerry N. L., Somogyi A. A., Bochner F., Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. British Journal of Clinical Pharmacology 1994; 38: 243–248
   PubMed Web of Science ®Google Scholar
• McKay G., Cooper J. K., Hawes E. M., Roy S. D., Midha K. K. Identification of new secondary metabolites of methoxyphenamine in man. Xenobiotica 1983; 13: 257–264
   PubMed Web of Science ®Google Scholar
• Midha K. K., Cooper J. K., McGilveray I. J., Coutts R. T., Dawe R. Metabolism of methoxyphenamine in man and in monkey. Drug Metabolism and Disposition 1976; 4: 568–576
   PubMed Web of Science ®Google Scholar
• Midha K. K., Hawes E. M., Cooper J. K., Hubbard J. W., Bailey K., McGilveray I. J. The identification of two new urinary metabolites of fenfluramine in man. Xenobiotica 1983; 13: 31–38
   PubMed Web of Science ®Google Scholar
• Penman B. W., Reece J., Smith T., Yang C. S., Gelboin H. V., Gonzalez F. J., Crespi C. L. Characterisation of a human cell line expressing high levels of cDNA-derived CPY2D6. Pharmacogenetics 1993; 3: 28–39
   PubMedGoogle Scholar
• Roy S. D., Hawes E. M., Hubbard J. W., McKay G., Midha K. K. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism. Lancet 1984a; 2(8416)1393
   PubMed Web of Science ®Google Scholar
• Roy S. D., McKay G., Hawes E. M., Midha K. K. Gas chromatographic quantitation of methoxyphenamine and three of its metabolites in plasma. Journal of Chromatography 1984b; 310: 307–317
   PubMed Web of Science ®Google Scholar
• Roy S. D., Hawes E. M., McKay G., Hubbard J. W., Midha K. K. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes. Canadian Journal of Physiology and Pharmacology 1985a; 63: 778–781
   PubMed Web of Science ®Google Scholar
• Roy S. D., Hawes E. M., McKay G., Korchinski E. D., Midha K. K. Metabolism of methoxyphenamine in extensive and poor metabolisers of debrisoquine. Clinical Pharmacology and Therapeutics 1985b; 33: 128–133
   Google Scholar
• Roy S. D., Hawes E. M., Midha K. K. Influence of urinary pH on the disposition of methoxyphenamine and its three metabolites in humans. Journal of Pharmaceutical Sciences 1987; 76: 427–432
   PubMed Web of Science ®Google Scholar
• Smith R. V., Rosazza J. P. Microbial models of mammalian metabolism. Journal Pharmaceutical Sciences 1975; 64: 1737–1759
   PubMed Web of Science ®Google Scholar
• Smith R. V., Rosazza J. P. Microbial models of mammalian metabolism. Journal of Natural Products 1983; 46: 79–91
   PubMed Web of Science ®Google Scholar
• Von Moltke L. L., Greenblatt D. J., Cotreau-Bibbo M. M., Duan S. X., Harmatz J. S., Shader R. I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. Journal of Pharmacology and Experimental Therapeutics 1994a; 268: 1278–1283
   PubMed Web of Science ®Google Scholar
• Von Moltke L. L., Greenblatt D. J., Cotreau-Bibbo M. M., Harmatz J. S., Shader R. I. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole, and quinidine. British Journal of Clinical Pharmacology 1994b; 38: 23–31
   PubMed Web of Science ®Google Scholar